Breaking News, Financial News

Lilly 4Q Results

Revenues up 45% and earnings up 101% driven by Mounjaro and Zepbound.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Lilly

Image courtesy of Lilly.

Lilly 4Q Revenues: $13.5 billion (45%) 4Q Earnings: $4.4 billion (+101%) FY Revenues: $45.0 billion (32%) FY Earnings: $10.6 billion (+102%) Comments: Growth in the quarter was driven by Mounjaro, with sales up 60% to $3.5 billion, and Zepbound, with sales of $1.9 billion. New Products revenue, which consists of Ebglyss, Jaypirca, Kisunla, Mounjaro, Omvoh and Zepbound, grew by $3.15 billion to $5.64 billion, led by Zepbound and Mounjaro. Growth Products revenue, which consists ...

Continue reading this story and get 24/7 access to Contract Pharma for FREE


Already a subscriber? Sign in

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters